{"id":"W3130048594","doi":"10.1158/1538-7445.sabcs20-pd1-05","title":"Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for <i>HER2</i>-mutant, hormone receptor-positive, metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Fulvestrant; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Population; Cancer; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002781545,0.000882442,0.001097076,0.0002358033,0.000519345,0.001383031,0.0009898683,0.0006514153,0.003556116],"category_scores_gemma":[0.001332182,0.0003109785,0.0008172126,0.0005089151,0.0004074356,0.0007275975,0.0006151859,0.001354075,0.0007787636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001268978,"about_ca_system_score_gemma":0.001628712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001907759,"about_ca_topic_score_gemma":0.005811283,"domain_scores_codex":[0.999332,0.0002868076,0.00004457102,0.0001190998,0.0001151539,0.0001023512],"domain_scores_gemma":[0.999018,0.0001447223,0.0002195297,0.00007240336,0.0001127934,0.0004326292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4923271,0.01060211,0.2031296,0.001271106,0.004256121,0.001346264,0.0004823468,0.003314017,0.05202014,0.0008160107,0.06732541,0.1631098],"study_design_scores_gemma":[0.2425434,0.1474453,0.5266916,0.000216069,0.006095688,0.003678994,0.0003604944,0.005421889,0.01289281,0.0009647455,0.05347767,0.000211327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9695382,0.003847447,0.0005212988,0.002118373,0.000142053,0.0008764238,0.01732603,0.0001009407,0.00552926],"genre_scores_gemma":[0.9492013,0.001811449,0.001739563,0.002205504,0.0003162685,0.001017891,0.04049542,0.00004795221,0.003164731],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003556116,"threshold_uncertainty_score":0.01471037,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06149143344151323,"score_gpt":0.4093802275949686,"score_spread":0.3478887941534553,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}